StockNews.com Begins Coverage on Senseonics (NYSE:SENS)

StockNews.com began coverage on shares of Senseonics (NYSE:SENS) in a report published on Wednesday morning. The brokerage issued a sell rating on the stock.

Separately, HC Wainwright reissued a buy rating and set a $2.00 price target on shares of Senseonics in a report on Wednesday, August 14th.

Senseonics Price Performance

NYSE SENS opened at $0.39 on Wednesday. The business’s fifty day moving average price is $0.42 and its 200-day moving average price is $0.48. The stock has a market capitalization of $206.57 million, a price-to-earnings ratio of -2.78 and a beta of 0.82. The company has a debt-to-equity ratio of 59.17, a current ratio of 3.11 and a quick ratio of 2.89. Senseonics has a 1-year low of $0.37 and a 1-year high of $0.75.

Senseonics (NYSE:SENS) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.03) earnings per share for the quarter, meeting the consensus estimate of ($0.03). The firm had revenue of $4.87 million for the quarter, compared to analysts’ expectations of $4.86 million. Senseonics had a negative return on equity of 299.69% and a negative net margin of 335.15%. On average, equities analysts predict that Senseonics will post -0.13 earnings per share for the current year.

Hedge Funds Weigh In On Senseonics

A number of institutional investors have recently bought and sold shares of SENS. RPO LLC purchased a new stake in Senseonics in the 4th quarter worth $37,000. State Board of Administration of Florida Retirement System purchased a new position in shares of Senseonics during the first quarter valued at about $91,000. Virtu Financial LLC purchased a new position in shares of Senseonics during the first quarter valued at about $162,000. Cubist Systematic Strategies LLC grew its position in shares of Senseonics by 25.9% during the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after purchasing an additional 85,501 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Senseonics by 16.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after purchasing an additional 51,000 shares in the last quarter. 12.36% of the stock is owned by institutional investors.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.